Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Pediatric Granule Ozanimod in Healthy Adults
NCT04528290Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration up to 14 days, Area Under the Curve to Infinity up to 14 days and 1 more. Started Oct 2020; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04528290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04528290.